Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.6
USERS' SCORE
Good
Based on 9 Reviews
8
Supplement Facts
Serving Size: 1 Veg Capsule
Amount Per Serving
%DV
Vitamin K2(as Menaquinone-7) (MK-7 ) (MenaQ7®)
100 mcg
**
Top Medical Research Studies
9
We aimed to discover how well PIVKA-II can predict treatment response in patients with non-AFP-secreting hepatocellular carcinoma (HCC) receiving systemic therapy.
By measuring PIVKA-II levels and assessing imaging after 8-12 weeks of treatment, we found a connection between PIVKA-II levels, tumor size, and treatment outcomes.
The study revealed a promising “50-50 rule” that can indicate prognosis based on PIVKA-II changes, making it a valuable marker for HCC treatment success.
By measuring PIVKA-II levels and assessing imaging after 8-12 weeks of treatment, we found a connection between PIVKA-II levels, tumor size, and treatment outcomes.
The study revealed a promising “50-50 rule” that can indicate prognosis based on PIVKA-II changes, making it a valuable marker for HCC treatment success.
Read More
8
We explored how a vitamin K precursor, known as menadione sodium bisulfite (MSB), influences prostate cancer progression in mice. Contrary to concerns surrounding antioxidants like vitamin E, our findings suggest that MSB acts as a pro-oxidant, successfully reducing cancer cell growth via oxidative cell death.
By targeting critical cellular pathways, MSB offers a new route for therapeutic intervention in prostate cancer. These results enhance our understanding of the effects of pro-oxidants and highlight potential opportunities for future treatments.
By targeting critical cellular pathways, MSB offers a new route for therapeutic intervention in prostate cancer. These results enhance our understanding of the effects of pro-oxidants and highlight potential opportunities for future treatments.
Read More
8
We investigated how vitamin K2 (VK2) influences the growth of cancer cells, particularly focusing on hepatocellular carcinoma (HCC). Our study centered on the interaction between VK2 and a protein known as HSD17B4, which is known to promote cancer cell proliferation. Previous research had shown that VK2 can bind to this protein, but we aimed to uncover the specific mechanisms behind its potential anti-cancer effects.
Through our experiments, we observed that VK2 can inhibit the growth of HCC cells by binding directly to HSD17B4. Interestingly, VK2 did not alter the expression levels of HSD17B4, which suggests that its impact on cell growth is due to other mechanisms. Specifically, we found that VK2 impedes the activation of important signaling pathways, including AKT and MEK/ERK, which play a critical role in cancer cell proliferation. As a result, this inhibition leads to decreased activity of another protein, STAT3, associated with cancer growth.
Moreover, VK2 demonstrated the ability to suppress the growth of transplanted tumors that were influenced by HSD17B4. These findings not only shed light on VK2's mechanism of action, but they also offer promising insights into its potential role in preventing or treating HCC in future applications.
Through our experiments, we observed that VK2 can inhibit the growth of HCC cells by binding directly to HSD17B4. Interestingly, VK2 did not alter the expression levels of HSD17B4, which suggests that its impact on cell growth is due to other mechanisms. Specifically, we found that VK2 impedes the activation of important signaling pathways, including AKT and MEK/ERK, which play a critical role in cancer cell proliferation. As a result, this inhibition leads to decreased activity of another protein, STAT3, associated with cancer growth.
Moreover, VK2 demonstrated the ability to suppress the growth of transplanted tumors that were influenced by HSD17B4. These findings not only shed light on VK2's mechanism of action, but they also offer promising insights into its potential role in preventing or treating HCC in future applications.
Read More
Most Useful Reviews
7.5
Antitumour properties
221 people found this helpful
Vitamin K2 is vital for calcium absorption and blood clotting. It redirects calcium from the blood to bone tissue, which is crucial for bone and dental health. Notably, in 2006, its antitumour properties were discovered, showing benefits against certain cancers, including lung, pancreatic, bladder, and rectal. Ongoing studies continue to explore its potential.
Read More
7.5
Antitumour benefits
210 people found this helpful
Vitamin K2 is essential for calcium absorption and blood clotting, supporting cardiovascular health. It redirects calcium to bones and teeth. In 2006, researchers found its potential to combat cancer, with promising results for lung, pancreatic, bladder, and rectum cancers. Research continues into its benefits against these diseases.
Read More
7.5
Cancer prevention
4 people found this helpful
Vitamin K2 is crucial for calcium absorption and blood clotting, ensuring cardiovascular health and bone integrity. Since its antitumour properties were discovered in 2006, it has shown efficacy against various cancers such as lung, pancreatic, bladder, and rectal. Research continues to affirm its benefits in these areas.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.6
- All Researches
9.5
We observed how vitamin K2 (VK2) could play a significant role in enhancing the effectiveness of a common treatment for acute myeloid leukemia (AML) called venetoclax (VEN). In our investigation, older patients diagnosed with AML showed promising responses to a treatment combination of VEN and another drug, azacitidine (AZA), alongside daily VK2 intake. Remarkably, we noted a complete response rate of about 79% among patients taking VK2, highlighting the potential of VK2 to improve treatment outcomes.
Our study involved patients who were mostly over 75 years old and considered high-risk. They received a regimen that included AZA and VEN, paired with VK2. We also looked into the mechanisms behind VK2's effects. We found that VK2 significantly increased apoptosis, a process that causes cancer cells to die, particularly through a pathway involving NOXA and MCL-1 proteins. This was driven by an increase in reactive oxygen species (ROS) induced by VK2.
Furthermore, the combination of VK2 and VEN worked synergistically to target two cancer-related proteins, enhancing the treatment's impact. This dual action could be a key factor in the strong clinical outcomes observed in our patient population. Given these exciting findings, further large-scale clinical trials are certainly warranted to explore VK2's role in cancer treatment more broadly.
Our study involved patients who were mostly over 75 years old and considered high-risk. They received a regimen that included AZA and VEN, paired with VK2. We also looked into the mechanisms behind VK2's effects. We found that VK2 significantly increased apoptosis, a process that causes cancer cells to die, particularly through a pathway involving NOXA and MCL-1 proteins. This was driven by an increase in reactive oxygen species (ROS) induced by VK2.
Furthermore, the combination of VK2 and VEN worked synergistically to target two cancer-related proteins, enhancing the treatment's impact. This dual action could be a key factor in the strong clinical outcomes observed in our patient population. Given these exciting findings, further large-scale clinical trials are certainly warranted to explore VK2's role in cancer treatment more broadly.
Read More
9
We aimed to discover how well PIVKA-II can predict treatment response in patients with non-AFP-secreting hepatocellular carcinoma (HCC) receiving systemic therapy.
By measuring PIVKA-II levels and assessing imaging after 8-12 weeks of treatment, we found a connection between PIVKA-II levels, tumor size, and treatment outcomes.
The study revealed a promising “50-50 rule” that can indicate prognosis based on PIVKA-II changes, making it a valuable marker for HCC treatment success.
By measuring PIVKA-II levels and assessing imaging after 8-12 weeks of treatment, we found a connection between PIVKA-II levels, tumor size, and treatment outcomes.
The study revealed a promising “50-50 rule” that can indicate prognosis based on PIVKA-II changes, making it a valuable marker for HCC treatment success.
Read More
8
EZJDD improves liver cancer outcomes
We evaluated the effectiveness and safety of Erzhu Jiedu Decoction (EZJDD) Granules in patients with mid-advanced liver cancer linked to hepatitis B.
In a study involving 132 patients, we randomly assigned them into two groups—one receiving standard treatment and the other receiving standard treatment along with EZJDD Granules for three months.
The results showed that EZJDD significantly extended progression-free survival and boosted the six-month survival rate, suggesting it may enhance treatment outcomes for this challenging condition.
In a study involving 132 patients, we randomly assigned them into two groups—one receiving standard treatment and the other receiving standard treatment along with EZJDD Granules for three months.
The results showed that EZJDD significantly extended progression-free survival and boosted the six-month survival rate, suggesting it may enhance treatment outcomes for this challenging condition.
Read More
8
We explored how a vitamin K precursor, known as menadione sodium bisulfite (MSB), influences prostate cancer progression in mice. Contrary to concerns surrounding antioxidants like vitamin E, our findings suggest that MSB acts as a pro-oxidant, successfully reducing cancer cell growth via oxidative cell death.
By targeting critical cellular pathways, MSB offers a new route for therapeutic intervention in prostate cancer. These results enhance our understanding of the effects of pro-oxidants and highlight potential opportunities for future treatments.
By targeting critical cellular pathways, MSB offers a new route for therapeutic intervention in prostate cancer. These results enhance our understanding of the effects of pro-oxidants and highlight potential opportunities for future treatments.
Read More
8
We examined the connection between fat-soluble vitamins, specifically vitamin K, and the progression of gliomas, which are particularly aggressive brain cancers. Using The Cancer Genome Atlas database, we found that vitamin K-related metabolic processes are closely linked with the severity and poor prognosis of gliomas.
Notably, a key gene, VKORC1, which is vital for vitamin K's function, showed a strong association with glioma aggressiveness. In laboratory settings, silencing this gene reduced glioma cell growth and movement. Although the results are promising, clinical effects in patients remain to be conclusively determined.
Notably, a key gene, VKORC1, which is vital for vitamin K's function, showed a strong association with glioma aggressiveness. In laboratory settings, silencing this gene reduced glioma cell growth and movement. Although the results are promising, clinical effects in patients remain to be conclusively determined.
Read More
User Reviews
USERS' SCORE
Good
Based on 9 Reviews
8
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Antitumour properties
221 people found this helpful
Vitamin K2 is vital for calcium absorption and blood clotting. It redirects calcium from the blood to bone tissue, which is crucial for bone and dental health. Notably, in 2006, its antitumour properties were discovered, showing benefits against certain cancers, including lung, pancreatic, bladder, and rectal. Ongoing studies continue to explore its potential.
Read More
7.5
Antitumour benefits
210 people found this helpful
Vitamin K2 is essential for calcium absorption and blood clotting, supporting cardiovascular health. It redirects calcium to bones and teeth. In 2006, researchers found its potential to combat cancer, with promising results for lung, pancreatic, bladder, and rectum cancers. Research continues into its benefits against these diseases.
Read More
7.5
Cancer prevention
4 people found this helpful
Vitamin K2 is crucial for calcium absorption and blood clotting, ensuring cardiovascular health and bone integrity. Since its antitumour properties were discovered in 2006, it has shown efficacy against various cancers such as lung, pancreatic, bladder, and rectal. Research continues to affirm its benefits in these areas.
Read More
9
Bleeding relief
7 people found this helpful
As a woman approaching 50, I faced irregular bleeding for two years. After testing for uterine cancer and hormone levels—both normal—I felt anxious. After starting vitamin K, the irregular bleeding ceased the next day. I will continue with it and monitor my progress.
Read More
8
Cancer and bones
3 people found this helpful
Vitamin K2 (MK-7) is integral to calcium absorption. Those on statins should consider supplements to mitigate osteoporosis and cardiovascular issues, as it fosters healthier bones and reduces calcification in arteries. Its role in improving blood clotting and driving proteins for heart health is vital.
Read More
Frequently Asked Questions
9
Bleeding relief
7 people found this helpful
As a woman approaching 50, I faced irregular bleeding for two years. After testing for uterine cancer and hormone levels—both normal—I felt anxious. After starting vitamin K, the irregular bleeding ceased the next day. I will continue with it and monitor my progress.
7.5
Cancer prevention
13 people found this helpful
I take vitamin K2 (MK7) with vitamin D3 to enhance calcium absorption. This product offers excellent value. With sufficient levels of K2, the risk of fractures reduces significantly. Its potential in halting autoimmune diseases and mitigating threats, including certain cancers, is significant.
7.5
Cancer protection
3 people found this helpful
I took vitamin K2 (MK7) alongside vitamin D3 for optimal calcium absorption. The cost-effectiveness is impressive. K2 reduces the risk of fractures and may help prevent autoimmune diseases and certain cancers, including prostate cancer. The synergistic effect with D3 is best achieved with dietary fats.
7.5
Antitumour properties
221 people found this helpful
Vitamin K2 is vital for calcium absorption and blood clotting. It redirects calcium from the blood to bone tissue, which is crucial for bone and dental health. Notably, in 2006, its antitumour properties were discovered, showing benefits against certain cancers, including lung, pancreatic, bladder, and rectal. Ongoing studies continue to explore its potential.
7.5
Anti-cancer properties
Taking vitamins K and D together is recommended. Vitamin K not only combats osteoporosis but also exhibits anti-cancer characteristics.
7.5
Cancer prevention
4 people found this helpful
Vitamin K2 is crucial for calcium absorption and blood clotting, ensuring cardiovascular health and bone integrity. Since its antitumour properties were discovered in 2006, it has shown efficacy against various cancers such as lung, pancreatic, bladder, and rectal. Research continues to affirm its benefits in these areas.
9.5
We observed how vitamin K2 (VK2) could play a significant role in enhancing the effectiveness of a common treatment for acute myeloid leukemia (AML) called venetoclax (VEN). In our investigation, older patients diagnosed with AML showed promising responses to a treatment combination of VEN and another drug, azacitidine (AZA), alongside daily VK2 intake. Remarkably, we noted a complete response rate of about 79% among patients taking VK2, highlighting the potential of VK2 to improve treatment outcomes.
Our study involved patients who were mostly over 75 years old and considered high-risk. They received a regimen that included AZA and VEN, paired with VK2. We also looked into the mechanisms behind VK2's effects. We found that VK2 significantly increased apoptosis, a process that causes cancer cells to die, particularly through a pathway involving NOXA and MCL-1 proteins. This was driven by an increase in reactive oxygen species (ROS) induced by VK2.
Furthermore, the combination of VK2 and VEN worked synergistically to target two cancer-related proteins, enhancing the treatment's impact. This dual action could be a key factor in the strong clinical outcomes observed in our patient population. Given these exciting findings, further large-scale clinical trials are certainly warranted to explore VK2's role in cancer treatment more broadly.
Our study involved patients who were mostly over 75 years old and considered high-risk. They received a regimen that included AZA and VEN, paired with VK2. We also looked into the mechanisms behind VK2's effects. We found that VK2 significantly increased apoptosis, a process that causes cancer cells to die, particularly through a pathway involving NOXA and MCL-1 proteins. This was driven by an increase in reactive oxygen species (ROS) induced by VK2.
Furthermore, the combination of VK2 and VEN worked synergistically to target two cancer-related proteins, enhancing the treatment's impact. This dual action could be a key factor in the strong clinical outcomes observed in our patient population. Given these exciting findings, further large-scale clinical trials are certainly warranted to explore VK2's role in cancer treatment more broadly.
8
We conducted a thoughtful phase II, randomized study to examine how vitamin K2 might boost the effectiveness of sorafenib, a drug commonly used to treat liver cancer. Our study involved 68 patients diagnosed with hepatocellular carcinoma, who were assigned to either a treatment group receiving sorafenib along with vitamin K2 or a control group receiving sorafenib alone.
The results painted a promising picture. In the group receiving vitamin K2, we observed a significant response rate of 27.3%, compared to only 4.5% in those taking sorafenib alone. Additionally, the average time patients could live without their cancer worsening was much longer in the vitamin K group—4.9 months versus 2.7 months for those on sorafenib only.
While we didn’t find a significant overall survival difference between the two groups, those in the vitamin K2 group who had a complete or partial response enjoyed a notably extended overall survival time—26.1 months compared to just 9.0 months for others in the vitamin K group and 11.5 months for the sorafenib-only group. Our findings suggest that vitamin K could play a role in enhancing cancer treatment outcomes when combined with sorafenib.
The results painted a promising picture. In the group receiving vitamin K2, we observed a significant response rate of 27.3%, compared to only 4.5% in those taking sorafenib alone. Additionally, the average time patients could live without their cancer worsening was much longer in the vitamin K group—4.9 months versus 2.7 months for those on sorafenib only.
While we didn’t find a significant overall survival difference between the two groups, those in the vitamin K2 group who had a complete or partial response enjoyed a notably extended overall survival time—26.1 months compared to just 9.0 months for others in the vitamin K group and 11.5 months for the sorafenib-only group. Our findings suggest that vitamin K could play a role in enhancing cancer treatment outcomes when combined with sorafenib.
4
We examined whether vitamin K (menatetrenone) could help prevent bone mineral density (BMD) loss in uterine cancer patients who underwent radiotherapy.
Our study involved 34 patients split into two groups: one receiving vitamin K and another not. While we found no significant BMD changes outside the radiation area, those on vitamin K did not experience the significant bone loss seen in the untreated group within the irradiated area.
While our results suggest a potential benefit of vitamin K, further research is needed to explore its role in improving patients' quality of life through fracture prevention.
Our study involved 34 patients split into two groups: one receiving vitamin K and another not. While we found no significant BMD changes outside the radiation area, those on vitamin K did not experience the significant bone loss seen in the untreated group within the irradiated area.
While our results suggest a potential benefit of vitamin K, further research is needed to explore its role in improving patients' quality of life through fracture prevention.
5
We investigated the potential link between dietary vitamin K2, also known as menaquinones, and breast cancer outcomes. The study involved a significant cohort, tracking 2,286 breast cancer cases and 207 deaths over a remarkable 702,748 person-years of follow-up.
Our exploration revealed that higher total intake of vitamin K2 was associated with an increased risk of developing breast cancer as well as an elevated risk of dying from it. Specifically, participants with the highest intake of vitamin K2 had a 26% greater risk of diagnosis and a 71% higher risk of mortality compared to those with the lowest intake.
Interestingly, while we found this concerning relationship with vitamin K2, the study did not show any significant links between overall vitamin K intake or phylloquinone (vitamin K1) and breast cancer. This indicates that if these findings are verified in future research, reducing dietary menaquinones could present a new strategy for preventing breast cancer.
Our exploration revealed that higher total intake of vitamin K2 was associated with an increased risk of developing breast cancer as well as an elevated risk of dying from it. Specifically, participants with the highest intake of vitamin K2 had a 26% greater risk of diagnosis and a 71% higher risk of mortality compared to those with the lowest intake.
Interestingly, while we found this concerning relationship with vitamin K2, the study did not show any significant links between overall vitamin K intake or phylloquinone (vitamin K1) and breast cancer. This indicates that if these findings are verified in future research, reducing dietary menaquinones could present a new strategy for preventing breast cancer.
References
- Bauer T, Richter-Eder S, Yasmin N, Jurkin J, Köffel R, et al. Vitamin K supports TGF-β1 depended human Langerhans cell differentiation and function via Axl. Front Immunol. 2025;16:1509228. doi:10.3389/fimmu.2025.1509228
- Chen SC, Ho HL, Liu CA, Hung YP, Chiang NJ, et al. PIVKA-II as a surrogate biomarker for therapeutic response in Non-AFP-secreting hepatocellular carcinoma. BMC Cancer. 2025;25:199. doi:10.1186/s12885-025-13568-4
- Kaneyasu Y, Fujiwara H, Akita T, Tanaka J, Shibata Y, et al. Suppressive effect of vitamin K (menatetrenone) against bone mineral density loss after radiotherapy in uterine cancer patients. Jpn J Radiol. 2025. doi:10.1007/s11604-025-01733-5
- Cheng Y, Wang HY, Wan CY, Shi JW, Jin YY, et al. Efficacy and Safety of Erzhu Jiedu Decoction Granules in Treating Mid-advanced Hepatitis B Virus-Associated Primary Liver Cancer Patients with Pi (Spleen)-Deficiency and Dampness-Heat Syndrome. Chin J Integr Med. 2024. doi:10.1007/s11655-024-3818-1
- Swamynathan MM, Kuang S, Watrud KE, Doherty MR, Gineste C, et al. Dietary pro-oxidant therapy by a vitamin K precursor targets PI 3-kinase VPS34 function. Science. 2024;386:eadk9167. doi:10.1126/science.adk9167
- Sasaki Y, Tokumura K, Yoshimoto M, Hinoi E. Association between Fat-Soluble Vitamin Metabolic Process and Glioma Progression. Biol Pharm Bull. 2024;47:1682. doi:10.1248/bpb.b24-00275
- Okabe S, Arai Y, Gotoh A. Vitamin K2 Protects Against SARS-CoV-2 Envelope Protein-Induced Cytotoxicity in Chronic Myeloid Leukemia Cells and Enhances Imatinib Activity. Int J Mol Sci. 2024;25. doi:10.3390/ijms252111800
- Tauchi T, Moriya S, Okabe S, Kazama H, Miyazawa K, et al. Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway. PLoS One. 2024;19:e0307662. doi:10.1371/journal.pone.0307662
- Okabe S, Gotoh A. Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells. BMC Cancer. 2023;23:827. doi:10.1186/s12885-023-11304-4
- Narvaez CJ, Bak MJ, Salman N, Welsh J. Vitamin K2 enhances the tumor suppressive effects of 1,25(OH)D in triple negative breast cancer cells. J Steroid Biochem Mol Biol. 2023;231:106307. doi:10.1016/j.jsbmb.2023.106307
- Jadhav N, Ajgaonkar S, Saha P, Gurav P, Pandey A, et al. Molecular Pathways and Roles for Vitamin K2-7 as a Health-Beneficial Nutraceutical: Challenges and Opportunities. Front Pharmacol. 2022;13:896920. doi:10.3389/fphar.2022.896920
- Lu X, Ma P, Kong L, Wang X, Wang Y, et al. Vitamin K2 Inhibits Hepatocellular Carcinoma Cell Proliferation by Binding to 17β-Hydroxysteroid Dehydrogenase 4. Front Oncol. 2021;11:757603. doi:10.3389/fonc.2021.757603
- Solmaz I, Ozdemir MA, Unal E, Abdurrezzak U, Muhtaroglu S, et al. Effect of vitamin K2 and vitamin D3 on bone mineral density in children with acute lymphoblastic leukemia: a prospective cohort study. J Pediatr Endocrinol Metab. 2021;34:441. doi:10.1515/jpem-2020-0637
- Haruna Y, Yakushijin T, Kawamoto S. Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study. Cancer Med. 2021;10:914. doi:10.1002/cam4.3674
- Wang K, Wu Q, Li Z, Reger MK, Xiong Y, et al. Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study. Clin Nutr. 2021;40:3370. doi:10.1016/j.clnu.2020.11.009
- Daisley BA, Chanyi RM, Abdur-Rashid K, Al KF, Gibbons S, et al. Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients. Nat Commun. 2020;11:4822. doi:10.1038/s41467-020-18649-5
